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Brain aging is characterized by considerable heterogeneity, including varying degrees of dysfunction in
specific brain systems, notably amedial temporal lobememory system and a frontostriatal executive system.
These same systems are also affected by neurodegenerative diseases. Recent work using techniques for
presymptomatic detection of disease in cognitively normal older people has shown that some of the late
life alterations in cognition, neural structure, and function attributed to aging probably reflect early neurode-
generation. However, it has become clear that these same brain systems are also vulnerable to aging in the
absence of even subtle disease. Thus, fundamental systemic limitations appear to confer vulnerability of
these neural systems to a variety of insults, including those recognized as typical disease and those that
are attributed to age. By focusing on the fundamental causes of neural system vulnerability, the prevention
or treatment of a wide range of late-life neural dysfunction might be possible.Howdoes the brain age? The causes of the changes in cognition,
neural function, and brain structure experienced by many older
people are debated. Specifically, do the neurodegenerative
diseases of older age often contribute to these problems, or is
there a ‘‘pure’’ age-related form of neural decline that is clearly
separate from disease? This question has occupied scientists
involved in the study of aging for decades but is now becoming
more tractable because of advances in techniques for studying
the human brain during life.
While heuristically useful, separating age and disease also
creates problems. First, what is ‘‘aging’’? There is no single
mechanism that underlies age-related change other than the
passage of time. Aging uncovers systemic limitations of human
biology that may be susceptible to a variety of deleterious
processes, someof which are related to frank disease and others
not. Distinguishing age and disease has led to the concept of
‘‘normal aging,’’ which may be defined as what is left when
disease is excluded. However, individuals in their seventh to
ninth decades without significant disease (vascular, metabolic,
or degenerative) are not statistically normal and are more aptly
described as ‘‘supernormal’’ or optimally aged (Rowe and
Kahn, 1987). Studies of such individuals may provide insight
into the intrinsic potential of human neural systems and could
lead to ways of optimizing function in aging that are completely
different from the methods for treating age-related disease.
Is our conceptualization of normal aging in fact contaminated
by the study of normal older people who are experiencing neuro-
degeneration? While for decades many studies of older people
may have excluded those with manifest disease, it has become
increasingly clear that neurodegeneration exists in subtle
preclinical forms for many years prior to symptom onset. The
use of norms to exclude individuals does not ameliorate these
problems since many presymptomatic individuals will test in
a normal range, and the norms themselves may have been
contaminated by participants with preclinical symptoms. In
fact, in-depth examination of many neural systems in olderpeople reveals alterations that have been attributed to normal
aging. But are such individuals ‘‘normal’’ in the sense of being
free of disease, or do age-related deficits simply reflect unde-
tected neurodegeneration?
What is the Behavioral Phenotype of Cognitive Aging?
Over decades, considerable effort has been devoted to defining
the cognitive profile of healthy (neurologically disease-free) older
people. A frequent shortcoming of these studies is the use of
cross-sectional as opposed to longitudinal data. Cross-sectional
data do not permit the differentiation of lifelong or developmental
subject characteristics from those that actually decline in older
age. Nevertheless, many studies have characterized older indi-
viduals using two general approaches. One can be defined in
terms of cognitive processes, while the other is more related to
neural systems; these are not mutually incompatible, and both
rely on examination of cognitive test performance. Regardless
of the approach, there is wide agreement that older people are
heterogeneous in their cognitive performance. Some older indi-
viduals have abilities typical of much younger people, while
others show marked decrements (Wilson et al., 2002). Further-
more, there is good agreement that some cognitive abilities,
particularly semantic memory or knowledge, are relatively
preserved with age (Park et al., 2002). The cognitive abilities
that most consistently decline with age are processing speed,
working memory, and episodic memory (Schaie, 1996; Park
et al., 2002). Models of cognitive aging that attempt to define
change in terms of fundamental cognitive processes that drive
general decline propose a small number of underlying cognitive
processes that are responsible for decline inmultiple areas; such
models generally include processing speed (Salthouse and Fer-
rer-Caja, 2003) or executive function (Hasher and Zachs, 1988)
as key factors. A major theory of cognitive aging attributes
many aspects of cognitive decline to loss of prefrontal cortical
function (West, 1996), although some aspects of episodic
memory are not well accounted for by this model. NeuralNeuron 77, January 23, 2013 ª2013 Elsevier Inc. 219
Figure 1. Neuropathology of Common Age-
Related Diseases
(A) Ab-immunostained senile plaques (arrows).
(B) Magnified view of an Ab-immunoreactive
cortical senile plaque.
(C) Tau-immunostained section of the hippo-
campus showing phospho-tau immunoractive,
NFT-bearing neurons (arrowheads) and the
granule cell layer of the hippocampus (arrows) with
some tau-immunoreactive neurons.
(D) Magnified view of neuron with NFTs (arrow-
heads).
(E) Low-magnification view of a small-vessel
infarct in the basal ganglia.
(F) Magnified basal ganglia infarct.
(G)BrainstemLewybody (arrow)andneuromelanin,
some of which is extraneuronal (arrowhead).
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decline in terms of two fundamental neural systems that support
episodic memory and executive function (Buckner, 2004; Hed-
den and Gabrieli, 2004). Differential decline of these cognitive
processes reflects varying degrees of involvement of the medial
temporal lobe memory system and a prefrontal cortex/striatal
executive system. The major late-life neurodegenerative disor-
ders affect these two neural systems differently and thereby
may explain some of the heterogeneity in brain aging. In addition,
there are other neural systems that are affected by age and
disease that will be discussed, and there are numerous other
systems that are not the focus of this Review.
Late-Life Neurodegenerative Diseases
Three common age-related diseases are the most likely culprits
in producing neural alterations attributed to normal aging: Alz-
heimer’s disease (AD), cerebrovascular disease (CVD), and Par-
kinson’s disease (PD). Relationships between these disorders
and aging could represent several different situations: manifest
neurodegenerative disease, presymptomatic neurodegenerative
disease, or a ‘‘phenocopy’’ of a neurodegenerative disease that
is actually based in a different mechanism.
Alzheimer’s Disease
Alzheimer’s disease is crucial to discussions of cognitive aging
simply because it is so prevalent; at least 1% of people at age
65 have AD, with prevalence rising at least to 30% by age 80
(Hofman et al., 1991). These figures reflect the presence of
dementia, a progressive diminution of cognitive abilities incom-
patible with independent functioning. AD usually begins with
anterograde amnesia, although other cognitive disturbances
can occur in the initial stage. AD evolves from more subtle
syndromes, often referred to as mild cognitive impairment
(MCI). While the strong age association of AD has at times re-220 Neuron 77, January 23, 2013 ª2013 Elsevier Inc.sulted in the belief that it represented
normative aging, it is amply clear that
many individuals live to late life without
dementia.
Many recent reviews have summarized
themolecular pathology, clinical features,
and therapeutic approaches to AD (Quer-
furth and LaFerla, 2010; Golde et al.,2011). The disease is defined by the association of cognitive
symptoms with the neuropathological findings of neuritic or
senile plaques and neurofibrillary tangles (NFTs) revealed on
histological examination of the brain (Figure 1). Plaques are
composed of the aggregated b-amyloid (Ab) protein surrounded
by dystrophic and degenerating neurites, while NFTs are com-
posed of themicrotubule-associated protein tau, which is hyper-
phosphorylated and aggregated as paired helical filaments. A
major theory of AD causation holds that soluble forms of Ab
initiate the disease, leading to alterations in synaptic structure
and function, followed by Ab aggregation into plaques (Hardy,
2009). This is consistent with evidence that reveals limited asso-
ciations between plaque Ab and dementia severity but stronger
associations between cognition and NFTs and synaptic number
and size (DeKosky and Scheff, 1990; Nelson et al., 2012). In its
full form, this amyloid cascade hypothesis holds that early
soluble Ab unleashes a chain of events causing alterations in
synapses and tau, and a host of downstream structural and
functional neural changes that are closely related to cognitive
decline.
Several issues complicate the differentiation of AD from
normal aging. First, the relationship between fundamental
features of AD pathology and cognition are tenuous. Recent
neuropathological criteria recognize that AD pathological
change can exist in the absence of symptoms (Hyman et al.,
2012), raising the likelihood that some individuals may be resis-
tant to the pathology. This is a particularly confusing situation in
the very old, where the relationship between AD pathological
change and cognition is particularly weak (Savva et al., 2009; Ba-
lasubramanian et al., 2012). Second, the pathology associated
with AD occurs in partial forms. NFTs, without Ab plaques, are
seen in many cognitively normal people, usually in medial
temporal lobe structures, and they increase exponentially with
Figure 2. PET Evidence of Fibrillar Brain Ab
Deposition in Normal Aging
[11C]PiB-PET scans.
(A) A patient with AD. Hotter colors indicate tracer
retention, or binding to Ab, throughout cortex. Ab
deposition is seen throughout cortex but particu-
larly in medial parietal and frontal regions (arrows),
areas associated with the default mode network.
(B) A normal older person with no evidence of
brain Ab. Cool colors indicate nonspecific uptake
primarily in white matter.
(C) A normal older person with extensive Ab
deposition in a pattern identical to that seen in AD.
(D) Quantitative tracer retention by age in a group
of young subjects (green), AD patients (blue), and
95 cognitively normal older people (red) from the
Berkeley Aging Cohort. The y axis is the distribu-
tion volume ratio (DVR), a quantitative index of total
brain tracer retention indicating the brain fibrillar Ab
load. Dotted yellow line indicates 2 SD above the
mean of young normal subjects DVR, a threshold
surpassed by 28% of the older normal subjects.
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affect entorhinal cortical neurons that project to dentate gyrus as
the perforant pathway, functionally disconnecting the hippo-
campus (Hyman et al., 1984). Ab plaques also occur in ‘‘diffuse,’’
as opposed to cored or neuritic forms, and these too are
commonly seen in cognitively intact older people (Knopman
et al., 2003). Whether these pathologies reflect early AD or
processes related to aging itself remains debated.
Cerebrovascular Disease
Stroke, or cerebral infarction, is also associated with both
advancing age and cognitive decline (Seshadri et al., 2006).
The most fulminant effect of stroke on cognition appears as
‘‘multi-infarct dementia’’ (Hachinski et al., 1974), but the preva-
lence of this disorder is argued. At least as important are many
other forms of cerebrovascular disease seen in aging, including
asymptomatic disease detected on imaging (O’Brien et al.,
2003). Othermanifestations of CVD include alterations in subcor-
tical white matter involving demyelination, rarefaction, and high
signal intensity on MRIs, thinning of cerebral cortex and cerebral
atrophy, and subclinical, silent infarction related to small vessel
occlusion (DeCarli et al., 1999; Vermeer et al., 2003) (Figure 1).
All of these forms of CVD have been linked with cognitive
dysfunction, are subtle or clinically undetectable in onset and
progression, and may play a role in age-related decline.
Parkinson’s Disease
Parkinson’s disease is a disorder of the motor system with
cardinal manifestations of slowing of motion (bradykinesia),
tremor, rigidity, and gait and postural instability. The character-
istic neuropathology involves loss of dopaminergic neurons in
the pars compacta of the substantia nigra (SN). These neurons,
which project to the striatum as the nigrostriatal pathway, also
contain Lewy bodies, an abnormally aggregated form of the
protein a-synuclein (Figure 1). PD has a strong age-associated
prevalence and is accompanied by cognitive dysfunction. Both
dementia (Aarsland et al., 1996) and mild cognitive impairmentNeuron 77(Litvan et al., 2012) are common in PD
patients. This type of major cognitive
dysfunction is associated with wide-spread limbic and neocortical Lewy body pathology as well as
concomittant AD pathology (Compta et al., 2011). However,
PD is also associatedwith a range ofmore subtle cognitivemani-
festations that may reflect dopamine deficiency.
Effects of AD Pathology in Normal Aging
Substantial AD pathology is consistently reported in postmortem
studies of older individuals who were cognitively normal prior to
death. About 20%–40% of cognitively normal individuals in their
eighth to ninth decades have at least intermediate levels of Ab
and NFT-tau pathology on autopsy examination (Bennett et al.,
2006; Kok et al., 2009); many of these people meet pathological
criteria for AD. This evidence has been used to assail the amyloid
cascade hypothesis, but adherents hold that such individuals
were in a stage of preclinical AD that would have progressed to
dementia had they lived longer. These peoplemay remain normal
because of neural compensation or reserve, which has been
conceptualized in two ways: a static or passive form of reserve,
often referred to as ‘‘brain reserve,’’ and a more dynamic form of
reserve, described as ‘‘cognitive reserve’’ or compensation
(Stern, 2002). Brain reserve implies that individuals differ in base-
line neural resources at the onset of age-related pathology,
perhaps because of developmental factors or the balance of life-
long positive and negative exposures. The dynamic concept of
reserve implies a more active compensatory process that could
represent functional reorganization that recruits additional neural
resources to maintain task performance. Individuals with AD
pathologywhomaintain normal cognition are the focus of intense
investigation because they may represent the earliest phase of
AD, and thus the types of individuals most amenable to therapy.
Such people clearly reside on the border of normal cognitive
aging and neurodegeneration.
A major technological advance for studying such individuals is
the development of radiolabeled tracers that bind to Ab that can
be imaged with positron emission tomography (PET) (Figure 2). A, January 23, 2013 ª2013 Elsevier Inc. 221
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available; the ligand [11C]PiB (or Pittsburgh compound B) has
been the most widely used (Klunk et al., 2004), with longer-
lived [18F]-labeled imaging agents recently available (Clark
et al., 2011). PET amyloid imaging detects only the fibrillar
aggregated forms of Ab, which is probably a later phenomenon
and less pathogenic than the soluble forms. In studies of
cognitively intact elderly, proportions of subjects with PET
evidence of fibrillar Ab deposition are congruent with the 20%–
30% rates seen with autopsy examination (Morris et al., 2010).
These values also agree with measurements of Ab obtained in
cerebrospinal fluid (CSF) (Jagust et al., 2009), where lower levels
of CSF Ab probably reflect increased deposition in insoluble
forms in the amyloid plaque. Although both CSF and PET
imaging show similar proportions of older people with evidence
of brain Ab, the majority of older people do not have evidence of
brain Ab deposition. Nevertheless, this technology makes it
possible to evaluate living people for the effects of Ab on neural
systems.
The ability to detect brain Ab deposition in older healthy adults
has resulted in intensive efforts to define cognitive performance
in such people, with somewhat conflicting results. While many
studies have failed to find any evidence of lower cognitive
performance (Aizenstein et al., 2008), a number have reported
subtle decrements in a host of cognitive abilities in those with
either imaging or pathological evidence of Ab. Most often this
is seen in episodic memory (Bennett et al., 2006; Pike et al.,
2011; Perrotin et al., 2012), although other cognitive domains
may be affected (Rodrigue et al., 2012). Longitudinal memory
decline also appears to be greater in those with evidence of
Ab (Storandt et al., 2009; Resnick et al., 2010). In studies that
report such cross-sectional or longitudinal decline, deficits are
quite small.
Preservation of cognitive ability could be due to reserve, or it
could reflect the fact that the full cascade of negative events
has not yet occurred. These downstream pathological alter-
ations appear to follow Ab in a sequence of events with prototyp-
ical ordering (Jack et al., 2010). Brain atrophy, for example, is
associated with Ab deposition in normals (Jack et al., 2009)
and hippocampal atrophy may mediate effects of Ab on cogni-
tion (Mormino et al., 2009) so that individuals with Ab who have
not yet developed these downstream changes could be spared
symptoms. Thus, older people with evidence of Ab may remain
normal because they have not expressed the full phenotype of
AD—they have amyloid pathologywithout clear evidence of neu-
rodegeneration and will look like all other older individuals on
every measure except Ab. However, mounting evidence sug-
gests that very subtle alterations in brain function may also be
present in such individuals.
Ab deposition is associated with disruption of large-scale
neural networks. These have been studied in the resting state
using the technique of functional connectivityMRI (fcMRI), which
makes use of the observation that spontaneous fluctuations in
the MRI signal occur synchronously within neural systems
(Biswal et al., 1995). These networks reflect sensory and motor
systems as well as ensembles of brain regions brought online
during tasks requiring memory, attention, or executive function
(Damoiseaux et al., 2006). These may be ‘‘task-positive’’222 Neuron 77, January 23, 2013 ª2013 Elsevier Inc.networks activated by externally directed cognitive tasks or
‘‘task-negative’’ networks that are deactivated during externally
driven cognition. The primary task-negative network, the default
mode network (DMN) (Raichle et al., 2001), is intrinsically discon-
nected in patients with AD (Greicius et al., 2004); a particularly
interesting observation since the pattern of Ab deposition in
the brain overlaps spatially with the topography of the DMN
(Buckner et al., 2005). The major nodes of this network include
precuneus/posterior cingulate, lateral parietal, and medial
prefrontal cortices, some of which also participate in memory
retrieval (Wagner et al., 2005). This network is also functionally
disrupted in cognitively intact older people with Ab (Hedden
et al., 2009) and also shows signs of atrophy (Becker et al.,
2011; Oh et al., 2011). During fMRI experiments of memory
encoding, older individuals deactivate the DMN less than
younger individuals and the degree of deactivation is inversely
proportional to the amount of Ab deposition (Sperling et al.,
2009) (Figure 3).
Increased fMRI brain activation in task-positive networks
during the performance of cognitive tasks has also been re-
ported in patients with AD (Grady et al., 2003), MCI (Dickerson
et al., 2004), and those with genetic risks for AD (Bookheimer
et al., 2000). Associations between increased activation and
better performance have led to the interpretation that such
changes are compensatory in nature. However, reduced activa-
tion has also been reported (Johnson et al., 2006) and studies
may vary considerably by disease stage of participants, the
cognitive task and its difficulty, and the particular brain regions
examined. Two studies reported increased activation during
memory encoding in older people who are amyloid positive
compared to those who are amyloid negative (Sperling et al.,
2009; Mormino et al., 2012), while one showed reduced
activation (Kennedy et al., 2012). Interestingly, looking at older
individuals as a group suggests that aging is associated with
diminished activation; differentiating older people by Ab deposi-
tion shows that older people who deposit Ab activate more than
young (Figure 3).
These studies point out the difficulty in generalizing about
‘‘aging’’ without also examining individuals for subtle signs of
brain disease. Many features seen with Ab deposition—decline
in episodic memory, brain atrophy, altered resting state func-
tional connectivity, and changes in brain activation—are
commonly ascribed to normal aging. Epidemiologic cohort
studies (Elias et al., 2000; Amieva et al., 2008) show that subtle
cognitive decline is seen in some normal individuals up to 12
years before the diagnosis of dementia, and studies of individ-
uals with autosomal dominant genetic causes of AD show
alterations in brain structure and function 10–15 years before
expected symptom onset (Bateman et al., 2012; Reiman et al.,
2012). Longitudinal studies of aging have also shown that indi-
viduals who remain cognitively stable over time have less
evidence of brain atrophy at baseline than those who subse-
quently decline, pointing out that studies of normal aging contain
at least some individuals destined for dementia (Burgmans et al.,
2009). Taken together, these observations make a strong case
that many of the cognitive and neural effects ascribed to normal
aging could be related to presymptomatic AD. A closer look,
however, suggests that the situation is not so clear.
Figure 3. Brain Activation and Deactivation during Memory Encoding
(A) Map of the topographic distribution of PiB retention in a group of older subjects.
(B) Deactivation in young subjects during the successful encoding of memories.
(C) Deactivation in older individuals without PiB retention is reduced in comparison to young.
(D) Deactivation in older individuals with PiB retention is further reduced. The patterns of PiB retention and deactivation reflect the default-mode network (DMN).
(A–D) are from Sperling et al. (2009), with permission.
(E) Pattern of activation (yellow/orange) and deactivation (blue) across all young and old subjects during encoding of scenes.
(F) Differences between young and old subjects in hippocampal brain activation (arrow) during successful memory encoding, indicating reduced activation
with aging.
(G) Same data as in (F) but shown as a function of PiB retention in the elderly, demonstrating higher activation in PiB+ elderly than young. (E–G) are fromMormino
et al. (2012), with permission.
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Anterograde amnesia is an early manifestation of AD, a subtle
feature of Ab deposition, and a common finding in normal aging.
With amyloid imaging, we can now exclude people with fibrillar
Ab to examine independent effects of age on cognition. Even
older individuals with no evidence of fibrillar brain Ab show
decline in visual memory and executive function compared to
young people (Oh et al., 2012), a strong point in favor of the
argument that presymptomatic AD does not explain all frontal/
executive and medial temporal/episodic memory dysfunction.
As amyloid imaging becomes more widely applied, it is likely
that we will see more cognitive investigations of normal older
people who have been screened for Ab.
There are also important differences between the patterns of
atrophy seen in aging and presymptomatic AD. Cross-sectional
and longitudinal studies reveal whole-brain volume loss in
normal individuals that includes gray and white matter and
begins in middle age, with rates of loss approximately doubledin AD patients (Fotenos et al., 2005). While this global volume
loss in AD is dramatic, investigation of individuals in early stages
is more revealing of specific regional vulnerabilities. Studies of
either patients with MCI or normal older people who subse-
quently develop AD show atrophy or cortical thinning in specific
regions including the entorhinal cortex (Stoub et al., 2005),
hippocampus (Jack et al., 1999), and precuneus, angular, and
supramarginal gyri (Davatzikos et al., 2009; Dickerson et al.,
2011). These regions overlap with the brain regions that are atro-
phic in cognitively normal people with evidence of Ab (Becker
et al., 2011; Oh et al., 2011). However, cross-sectional and longi-
tudinal studies of aging show prominent volume loss in both
prefrontal cortex (PFC) (Raz et al., 1997; Resnick et al., 2003; Fjell
et al., 2009) and striatum (Raz et al., 2003b), which are neither
associated with Ab nor implicated in the subsequent develop-
ment of AD. This frontostriatal atrophy, which has been concep-
tualized as the substrate for the ‘‘frontal hypothesis’’ of cognitive
aging, must have other explanations than AD or Ab. Furthermore,Neuron 77, January 23, 2013 ª2013 Elsevier Inc. 223
Figure 4. Pathological and Imaging Evidence of White Matter
Disease
Normal white matter seen on gross inspection (A) and microscopically (B).
Severe white matter pallor (C) indicating rarefaction and demyelination
microscopically (D). These findings are consistent with white matter hyper-
intensities (E), which characteristically surround the ventricles throughout
subcortical white matter (arrow). TheseWMHs also disrupt fiber tracts, seen in
(F) using diffusion tensor imaging tractography.
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factors related to AD (such as genetic risks and Ab) and never-
theless show substantial age-related brain atrophy, even in
AD-related areas like entorhinal cortex (Fjell et al., 2012). In the
aggregate, these data do not support a unitary etiology of age-
related atrophy that is caused by preclinical AD.
Dysfunction of the DMN, while associated with Ab deposition,
has also been seen in studies of normal aging both as discon-
nection in resting state studies (Damoiseaux et al., 2008) and
as reduced deactivation during tasks requiring semantic classi-
fication (Lustig et al., 2003) and episodic memory encoding
(Miller et al., 2008). While the similarities between these aging
studies and Ab-related findings are striking, older individuals
with no evidence of brain Ab also show reduced deactivation
of the DMN during memory encoding (Vannini et al., 2012) and
reductions in resting state DMN connectivity (Andrews-Hanna
et al., 2007). Thus, older people both with and without evidence
of fibrillar Ab share a fundamental disruption in the function of the
major task-negative network. This mechanism underlying this
neural ‘‘phenocopy’’ of AD in Ab-free aging is unexplained.
A variety of cognitive tasks have been associated with
increased fMRI evidence of neural activation in PFC in normal
older adults compared to younger adults. This is often accompa-
nied by reduced activation elsewhere in the brain and a tendency
for older people to activate both hemispheres when younger
people activate unilaterally (Cabeza et al., 1997). A widely
hypothesized explanation for this effect involves PFC com-
pensation for failing neural function elsewhere, such as the
hippocampus (Daselaar et al., 2006). A recent meta-analysis
that considered both task demands and performance reported
significant trends for increases in activation in dorsolateral
PFC in older compared to younger individuals, with greater224 Neuron 77, January 23, 2013 ª2013 Elsevier Inc.activation in the young in more ventral PFC, occipital cortex
(particularly during perceptual tasks), and hippocampus (Spreng
et al., 2010). These types of observations have resulted in
cognitive models that have stressed compensation, particularly
in PFC, as a response to age-related change (Reuter-Lorenz
and Lustig, 2005; Park and Reuter-Lorenz, 2009). At this
point, it is difficult to assess the extent to which such activa-
tion-related changes might be due to presymptomatic AD. The
constellation of reduced activation in a typically AD-affected
region, the hippocampus, with increased age-related activation
in a typically AD-spared region, the PFC, suggests that preclin-
ical AD could underlie some of these findings. However, there
are as yet too few studies of normal older people with measured
brain Ab to draw substantial conclusions. Increases in activation
in aging are unlikely to have a single explanation. Future
studies will need to examine interactions between task difficulty,
behavioral performance, brain regions, and biomarkers of
presymptomatic AD.
Normal aging, AD, and preclinical AD share the interesting
features of anterograde amnesia, brain atrophy, network
dysfunction, and increased cognitive activation. Based on these
similarities, as well as the likelihood that normal cognitive aging
studies to date have included a fair proportion of people with
substantial brain Ab accumulation, it is tempting to consider
that many of the features of normal aging represent subtle forms
of AD. However, it is important to keep in mind that most older
people do not express fibrillar Ab deposition. Furthermore,
a small number of recent studies that compare older people
without brain evidence of Ab to young people show age-related
alterations in cognition, atrophy, resting state networks, and
brain activation. This could reflect our inability to fully exclude
AD, or it could be that the identical neural systems show the
same kind of vulnerability to the different processes of aging
and disease.
Cerebrovascular Disease and Cognitive Aging
Studies of cognitively normal older individuals can exclude
participants with overt or symptomatic CVD by careful clinical
examination since such individuals usually have neurological
symptoms affecting motor and sensory systems that are
straightforward to detect. However, 20%–30% of older people
also have asymptomatic cerebrovascular disease such as
infarction, microbleeds, and microinfarcts (Vermeer et al.,
2003; Jeerakathil et al., 2004). Another category of vascular
pathology frequently seen on MR scans of older individuals is
white matter hyperintensities (WMHs) (Figure 4). These areas of
increased MR signal seen on T2 and FLAIR images have been
strongly associated with a host of vascular risk factors and the
pathological changes of white matter rarefaction and demyelin-
ation (Breteler et al., 1994; Jagust et al., 2008). Although MR
scanning could exclude most such individuals from studies of
normal aging, microinfarcts pose challenges. Many normal aging
studies do not exclude such individuals because WMHs and
similar findings might be considered part of normal aging,
because microinfarcts are undetectable, or because MR scans
may not have been performed.
There is ample evidence that these vascular pathologies affect
cognition in normal older people without dementia or MCI.
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2004) and regardless of their location tend to have effects on
glucose metabolism that preferentially affect prefrontal cortex,
and behavioral effects on executive function (Gunning-Dixon
and Raz, 2003; Tullberg et al., 2004; Marchant et al., 2012).
WMHs are associatedwith a typical age-related cognitive deficit,
failure of cognitive control, as well as with failure to activate PFC
during tasks requiring cognitive control (Mayda et al., 2011).
Even the risk factors for CVD affect PFC structure and function.
Higher scores on the Framingham Cardiovascular Risk Profile
are associated with reductions in glucose metabolism in PFC
(Kuczynski et al., 2009) and hypertension is associated with
reductions in prefrontal cortical volume and decline in executive
function tasks (Raz et al., 2003a). A strong chain of evidence thus
links CVD and cerebrovascular risk, PFC atrophy, and decline in
prefrontal cognition in aging, suggesting that at least part of the
frontal hypothesis of aging could be mediated by cerebrovas-
cular disease.
It is likely, however, that the neural mechanisms linking CVD to
behavior are even more pervasive, as WMHs are not only asso-
ciated with decline in executive function but also memory
(Gunning-Dixon and Raz, 2000). While memory decline in aging
could reflect involvement of PFC in strategic processing, there
is ample evidence for direct hippocampal effects. Hypertension
is associated with hippocampal atrophy (Raz et al., 2005), and
WMHs are associated with reduced activation in the medial
temporal lobes during memory encoding (Nordahl et al., 2006).
CVD thus affects both major neural systems that have been
associated with cognitive aging: the PFC/executive system
and the medial temporal lobe memory system.
Manifestations of cerebrovascular disease can be general-
ized, subtle, and temporally remote. For example, levels of
blood pressure at midlife are associated with greater cerebral
atrophy in late life (DeCarli et al., 1999). The precise mechanisms
mediating relationships between vascular disease or risk factors
and volume loss are unknown but could involve loss of white
matter volume, microbleeds, or microinfarcts. A role for chronic
ischemia in the etiology of WMHs or cortical atrophy has been
proposed but never proven. Reduced white matter integrity,
measured with the MR technique of diffusion tensor imaging
(DTI), is also related to a crucial cognitive phenomenon in aging,
loss of processing speed (Burgmans et al., 2011). Decreases in
functional connectivity within the DMN in older subjects are also
related to loss of white matter integrity revealed by DTI (An-
drews-Hanna et al., 2007). However, the biological basis of
these DTI findings is unclear. Associations between DTI
changes and WMHs and between DTI changes and some
measures of cerebrovascular disease (Nitkunan et al., 2008)
suggest that vascular factors may play a role. Whether these
DTI changes reflect a vascular etiology of age-associated cogni-
tive decline responsible for processing speed and network
alterations or whether they reflect disease-free aging remains
to be determined.
The evidence is thus overwhelming that CVD, like AD, exists in
subtle forms in many older people. Interestingly, exclusion of
normal subjects with either cerebrovascular risk factors or overt
cerebrovascular disease attenuates (though does not remove)
both age-related cognitive decline and longitudinal brain atrophy(Head et al., 2002; Resnick et al., 2003). CVD affects both neural
systems that decline with age and is thereby implicated in
decline of executive and memory function. Based on this
evidence, it is reasonable to conclude that subtle forms of cere-
brovascular disease have contributed to our conceptualization
of aging, and that this group of disorders and risk factors may
be at least partly responsible for both frontal and medial
temporal theories of cognitive aging. Most importantly, many
factors associated with CVD such as hypertension, obesity,
and diabetes are treatable, an argument against the inevitability
of at least some aspects of cognitive aging.
Parkinson’s Disease and Cognitive Aging
While PD is characteristically a disorder of movement, cognitive
decline and dementia are common symptoms in PD patients that
are most often associated at postmortem with widely distributed
Lewy bodies or concommitant AD pathology (Jellinger, 2013).
However, these pathological processes fail to account for
many cases of PD-associated cognitive decline (Libow et al.,
2009). In fact, the essential neurochemical disturbances associ-
ated with PD provide a compelling explanation for some forms of
age-related cognitive decline. In addition to degeneration of the
SN, neurons in the ventral tegmental area (VTA) also degenerate
in PD. Both the VTA and SN contain neurons that project to
limbic and cortical regions involved in cognition (Bjo¨rklund and
Dunnett, 2007). Cognitive deterioration in PD is associated with
loss of both VTA neurons and neurons in the medial part of the
SN that project to the dorsal caudate (Rinne et al., 1989; Zweig
et al., 1993). These findings have implications for a neurochem-
ical basis of age-related cognitive decline.
The dopaminergic deficits of PD provide a useful model for
understanding the neurochemical changes that underlie cogni-
tive aging. PD patients show dysfunction in cognitive processes
that rely upon dorsolateral PFC abilities and include planning,
temporal sequencing, delayed response, and set shifting (Pillon
et al., 1986; Postle et al., 1997). These neuropsychological
deficits have been investigated using PET to study in vivo
measures of neurochemistry. Such studies have made use of
dopamine precursor molecules such as 18F-labeled Fluorodopa
(FDOPA) and fluorometatyrosine (FMT, Figure 5) to study dopa-
mine synthesis in the presynaptic neuron and also a variety of
radio-labeled ligands that bind to the dopamine transporter
(DAT) on the presynaptic neuron. Such studies have shown
relationships between lower caudate FDOPA uptake (Bru¨ck
et al., 2001), reduced DATs (Marie´ et al., 1999), and impaired
cognition in PD patients. The loss of nigral dopaminergic input
to the dorsolateral caudate probably plays a key role in
prefrontal cognitive dysfunction because caudate is anatomi-
cally linked to PFC through the striato-thalamo-cortical func-
tional loops (Alexander et al., 1986). There is also in vivo PET
evidence for loss of extrastriatal dopamine (Klein et al., 2010)
and for reduced PFC glucose metabolism (Polito et al., 2012)
and neural activation (Carbon et al., 2004) that correlates with
dopamine loss.
Could these strong links betweenmidbrain dopaminergic neu-
rodegeneration, striatal dopamine loss, and failure on prefrontal
cognitive tasks in PD find a correlate in normal cognitive aging?
The link between dopamine and prefrontal cognition is wellNeuron 77, January 23, 2013 ª2013 Elsevier Inc. 225
Figure 5. In Vivo Dopamine Imaging and Relationships to Brain Function
(A) Uptake of the dopamine synthesis tracer [18F]-fluorometatyrosine (FMT) in a normal individual. Hotter colors indicate tracer uptake in presynaptic neurons in
striatum (yellow arrows) and brainstem (red arrow).
(B) Correlation between performance on the listening span test, a test of working memory, and dopamine synthesis measured with FMT. Hot-colored voxels
(indicated with red arrow) are regions in which greater dopamine function is associated with better working memory performance in a group of older individuals.
(C) Correlation of caudate dopamine synthesis with brain activation in the left middle frontal gyrus. Higher dopamine synthesis was associated with greater
activation during the delay phase of a working memory task. (B) and (C) are from Landau et al. (2009), with permission.
(D) Regions in which binding potential at the D1 receptor was reduced in young people performing the multisource interference task. Reduced binding potential
reflects release of endogenous dopamine.
(E) Changes in binding potential by age in the same experiment as (D). Younger individuals show evidence of dopamine release, while older individuals do not. (D)
and (E) are from Karlsson et al. (2009), with permission.
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(Arnsten, 2011). In addition, there are compelling similarities
between the neurochemical and motoric aspects of PD and
aging. Nigral dopaminergic loss is a feature of aging itself.
Studies of postmortem tissue have revealed loss of nigral dopa-
minergic neurons and DATs at a rate of 5%–8%/decade (Fearn-
ley and Lees, 1991; Ma et al., 1999). These postmortem
measures are paralleled by multiple in vivo PET studies showing
age-associated loss of DATs (Volkow et al., 1994), vesicular
monoamine transporters (a marker of presynaptic dopaminergic
neurons) (Frey et al., 1996), and D2 dopamine receptors (Volkow
et al., 1998) in the striatum. Although the high density of dopami-
nergic terminals and receptors in the striatum make that region
most amenable to reliable PET measurement, recent methods
for investigating this system in extrastriatal regions have shown
age-associated loss of D2 receptors in PFC and MTL (Kaasinen
et al., 2000) consistent with degeneration of mesocortical and
mesolimbic projections. Community studies that have examined226 Neuron 77, January 23, 2013 ª2013 Elsevier Inc.the prevalence of parkinsonism note that at least 15%–30% of
older individuals show motor impairment similar to but less
severe than those with full-fledged PD (Bennett et al., 1996;
Uemura et al., 2011). A community-based study with autopsy
follow-up, in fact, linked the presence of such parkinsonian
symptoms in normal older people to loss of nigral neurons
(Ross et al., 2004). Finally, in addition to the well-recognized
association between frontal atrophy and aging, one of the brain
regions showing the strongest and most consistent age-associ-
ated shrinkage is the striatum (Raz et al., 2003b). Although this
has not been directly related to loss of dopaminergic input, the
rate of striatal volume loss with advancing age parallels the
rate of dopamine loss in aging.
Straightforward evidence of a dopamine-deficiency substrate
of cognitive aging comes from studies that have used PET
measurements of dopamine function to explain individual differ-
ences in the cognitive performance of older people. This work
has shown associations between D2 receptors or DATs and
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episodic memory, semantic memory, perceptual speed, and
spatial cognition (Volkow et al., 1998; Ba¨ckman et al., 2000;
Erixon-Lindroth et al., 2005; Reeves et al., 2005). There are
strong relationships between dopamine synthesis and working
memory (Landau et al., 2009) and between D1 receptors and
variability in cognitive performance in aging (MacDonald et al.,
2012). Some evidence suggests that older people upregulate
dopamine synthesis in the striatum as a potential compensatory
mechanism (Braskie et al., 2008). Another powerful approach
involves measuring actual dopamine release by using a PET
receptor ligand that can be displaced by endogenous dopamine.
In one such study, younger individuals showed evidence of
dopamine release in the striatum during an interference task,
while dopamine release was not detectable in the older group
(Karlsson et al., 2009) (Figure 5).
A few studies have paired PETmeasurement of dopamine with
fMRI measures of brain activation to link neurochemistry to
neural activity in aging. Caudate dopamine synthesis is associ-
ated with activation in PFC in older people during the
delay period of a working memory task (Landau et al., 2009),
findings that parallel dopamine-dependent PFC delay period
neural activity in primate electrophysiological studies of work-
ing memory (Goldman-Rakic, 1996). Functional connectivity
between PFC and caudate during the delay period was greater
in younger than older subjects, and greater connectivity was
associated with both better working memory performance and
lower dopamine synthesis, supporting the observation that
increased synthesis might reflect compensatory processes in
a deficient system (Klostermann et al., 2012). Dopamine may
also affect allocation of cognitive resources by modulating
deactivation during cognition. Greater dopamine synthesis is
associated with more DMN deactivation in young people, but
this relationship is lost in older individuals (Braskie et al., 2011).
Similar relationships between dopamine, brain activation, and
cognitive performance in aging have been seen in studies that
used PET to examine dopamine receptors. Numerous studies
have shown an age-related blunting of the load-related increase
in brain activation during working memory tasks that could indi-
cate failure of neural recruitment in the face of amore demanding
task. Dopamine D1 receptor density in the caudate explains
a substantial proportion of the variance in BOLD response in
PFC in this situation (Ba¨ckman et al., 2011). This underrecruit-
ment could be reproduced in younger subjects given a D1
receptor antagonist (Fischer et al., 2010).
Does PD explain cognitive aging? From the perspective of
typical PD—that is, a movement disorder associated with the
deposition of brainstem Lewy bodies and dopamine defi-
ciency—PD seems an unlikely explanation for much of cognitive
aging. However, subtle changes in motor function are common
in aging as is loss of dopaminergic neurons and many dopami-
nergic neurochemical measures. There is also strong evidence
linking these dopamine losses to decline in cognitive function
with age and specifically to alterations in both the frontostriatal
executive system and the DMN. While this dopamine deficiency
probably does not necessarily reflect incipient PD, it shares
behavioral and neural similarities implicating dopamine loss as
a fundamental mechanism of cognitive aging.Differentiating Age and Disease in the Brain: Animal
Models
If studies of cognitive aging have included people with subtle
forms of AD, CVD, and PD, is there any way to define mecha-
nisms of brain aging that are independent of these disorders?
While the careful application of techniques for characterizing
older subjects, such as amyloid imaging or structural brain
imaging offers considerable promise, animal models of naturally
occurring aging phenomena can also be helpful in establishing
aging phenotypes. Although some old animals, including dogs
and monkeys, show evidence of amyloid plaque accumulation
(Selkoe et al., 1987), they do not show full-blown evidence of
AD or other neurodegenerative disorders that complicate the
study of aging. Rodents and primates both exhibit signs of aging
that are similar to those seen in humans including behavioral
deficits, structural and ultrastructural alterations, and changes
in electrophysiology (Yeoman et al., 2012). These deficits may
or may not be driven by mechanisms identical to those that
underlie human aging, as there is no a priori theory that necessi-
tates common cross-species mechanisms of aging. Neverthe-
less, these animal models may generate approaches to human
aging that offer the potential for revealing fundamental age-
associated mechanisms of decline.
Studies of aged monkeys have conclusively demonstrated
age-associated performance decrements on a variety of behav-
ioral tasks that reflect function of both dorsolateral PFC and
medial temporal lobe systems. Modern anatomic studies have
failed to detect substantial neuronal loss in either of these
regions (Amaral, 1993; Peters et al., 1994; Hof et al., 2000). In
the dlPFC, the morphological changes that appear best corre-
lated to declining performance with age involve alterations in
synapses (Peters et al., 2008). This includes loss of synapse
density and apical dendritic branching that particularly affects
the small, thin spines most involved in plasticity (Dumitriu et al.,
2010). These spines may be affected by disinhibition of cAMP
signaling; a recent study indicated that inhibition of cAMP
signaling in old monkeys restored neuronal activity during the
delay period of aworkingmemory task (Wang et al., 2011). These
findings unify structural and neurochemical theories of PFC
aging using animal models that do not reflect the common
neurodegenerative diseases like AD and PD.
Age-related change in the primate medial temporal lobe
involves loss of spine and synapse density in the subiculum
(Uemura, 1985a, 1985b), as well as alterations in the proportions
of multiple-synapse boutons and nonsynaptic boutons in the
outer molecular layer of the dentate gyrus (DG) (Hara et al.,
2011). In rodents, aging is also associated with loss of synapses
in DG (Geinisman et al., 1992) and loss of synaptophysin in DG
andCA3 (Smith et al., 2000) that is attributable to loss of DG input
via the perforant pathway. A multimodal/multispecies imaging
approach used fMRI in monkeys to measure cerebral blood
volume (CBV), a correlate of neuronal function, and Arc gene ex-
pression in rats, an immediate early gene whose expression is
related to neuronal activity (Small et al., 2004). Results indicated
age-associated loss of CBV and arc gene expression in only
the DG in both species. Furthermore, CBV was related to behav-
ioral performance on thedelayednonmatch to sample task, a test
of memory that draws upon medial temporal lobe resources.Neuron 77, January 23, 2013 ª2013 Elsevier Inc. 227
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primate are clear. There is extensive evidence for synaptic
changes throughout neocortex in association with human aging.
This includes reduction in dendritic spine density, volume, and
length seen across the lifespan in multiple cortical regions
(Jacobs et al., 1997; Benavides-Piccione et al., 2012). Neuronal
loss, historically considered a major aspect of brain aging, is
probably minimal, while the synaptic alterations predominate.
Nevertheless, loss of specific neuronal types may play important
roles. This is particularly true in the medial temporal lobe, where
differential vulnerability to age and disease has been noted. The
entorhinal cortex is susceptible to AD pathology, with involve-
ment by NFTs and loss of the perforant pathway providing input
from the entorhinal cortex to the dentate gyrus (Hyman et al.,
1984). Age, in contrast, appears to be associated with neuronal
loss in the hilus of the dentate gyrus and the subiculum (West
et al., 1994), while notably sparing CA1–CA3. Although AD is
also associated with neuronal loss in the hilus and subiculum,
CA1 is an interesting region in demonstrating considerable
AD-related neuronal loss without showing age effects (West
et al., 1994; Price et al., 2001).
Taken together, these data suggest two types of age-related
morphological alterations distinct from neurodegeneration that
occur in animals and humans. One is loss of synaptic density,
particularly in PFC. The other is neuronal loss in the DG that is
related to age and not disease and that may reflect loss of
synaptic input, via the perforant pathway. Conversely, loss in
CA1 and entorhinal cortex is more likely to reflect the presence
of AD. These findings can inform investigations of age-related
cognitive decline in humans that may reflect aging, as opposed
to neurodegenerative, phenotypes.
Are There Nondegenerative Aging Phenotypes of Neural
Function?
While standard clinical approaches to the investigation of
memory in aging have been very helpful in defining relationships
between age and disease, more mechanistic behavioral
approaches offer additional promise in this regard. For example,
the dual-process theory of episodic memory contrasts recollec-
tion as a relatively precise reconstruction of the details of an
event, while familiarity is conceptualized as a more vague sense
of ‘‘knowing’’ or previous experience. Studies consistently find
age-related failure of recollection but less consistent failure of
familiarity (Jennings and Jacoby, 1993), while patients with AD
show failure in both processes. One controversial model posits
that recollection is related to hippocampal function and famil-
iarity to extrahippocampal medial temporal lobe structures.
This dissociation has been seen in studies that have used MRI
to measure the volumes of these structures in aging and
dementia (Yonelinas et al., 2007; Wolk et al., 2011). These
studies provide some evidence for a distinction between aging
and AD based in hippocampal anatomy, since AD effects on
both hippocampus (CA1) and entorhinal cortex may have their
behavioral correlate in loss of familiarity and recollection, while
aging is better related to hippocampally mediated (i.e., DG)
deficits in recollection.
Another behavioral approach to the study of memory has
relied upon computational models of hippocampal function228 Neuron 77, January 23, 2013 ª2013 Elsevier Inc.emphasizing pattern separation and pattern completion.
Reviewed elsewhere (Yassa and Stark, 2011), this approach
compares how the hippocampus manages representations
that share features to either match degraded representations
to stored templates (i.e., pattern completion) or to differentiate
representations with similar features from previously stored
information (i.e., pattern separation). These functions permit,
respectively, the processes of generalization and the ability to
encode novel information as distinct from prior, similar informa-
tion. Considerable evidence links the DG to performance of
pattern separation and, predictably, older adults show deficits
on a task requiring the separation of spatial patterns (Stark
et al., 2010). However, such deficits share features of AD since
they occur in individuals with evidence of greater age-related
impairment, and because they are also seen in patients with
MCI (Yassa et al., 2010).
Studies using imaging approaches have recently begun to
investigate subregions of the hippocampus with both structural
and functional methods. High-field MRI permits higher resolu-
tion and contrast and therefore differentiation of hippocampal
fields. In general, AD tends to involve volume loss in the subic-
ulum and CA1 (Fouquet et al., 2012) and age affects volume
in CA3/DG (which cannot be differentiated on these images)
(Mueller and Weiner, 2009) (Figure 6), although some studies
have found that age may also be associated with loss in CA1
(Mueller and Weiner, 2009) and subiculum (La Joie et al.,
2010). Memory performance in older people has been linked
to CA3/DG volume, while atrophy in CA1 was related to the
presence of cerebrovascular risk factors (Shing et al., 2011).
This again suggests a relative specificity of some subregions
for age and others for disease, in this case of a vascular
nature. It is important to keep in mind the limitation of these
studies, particularly limits in resolution that may make indepen-
dent measures of neighboring regions difficult, and the fact that
older individuals could still be in preclinical stages of AD.
However, a search for regional specificity in the hippocampus,
especially if paired with measures of Ab and cerebrovascular
disease, offers potential for defining age-specific morpholog-
ical alterations.
These morphological alterations have functional correlates
aswell. Initial studies used a form of resting fMRI data acquisition
to investigate steady-state blood flow as an index of basal hippo-
campal function (Small et al., 2002), demonstrating age-related
decline in hippocampal function in the DG and subiculum as
distinct from entorhinal cortex. Application of the pattern separa-
tion paradigm has also produced interesting results; older
individuals show greater activation in CA3/DG than younger
subjects performing this task while also showing a tendency
for pattern completion, rather than separation (Yassa et al.,
2011a). These findings have been linked to a loss of DG input
via the perforant pathway, seen using DTI techniques (Yassa
et al., 2011b). It is interesting to note that functional loss in the
DG related to perforant pathway damage is seen in pathological
processes common to animal models of aging, older humans,
and the NFT pathology of AD. This is an excellent example of
how a single neural system is vulnerable to a variety of insults
that may reflect both age-related and neurodegenerative
processes.
Figure 6. Human Hippocampus in Cross-
Section and MR Images
(A) Coronal cross-section of human temporal lobe.
DG, dentate gryrus; S, subiculum; PrS, pre-
subiculum; EC, entorhinal cortex; cs, collateral
sulcus; FG, fusiform gyrus; its, inferior temporal
sulcus; ITG, inferior temporal gyrus; mts, middle
temporal sulcus; MTG, middle temporal gyrus; sts,
superior temporal sulcus; STG, superior temporal
gyrus.
(B) Coronal MRI view indicating location of hippo-
campus (arrow).
(C and D) High-field MRI images showing hippo-
campus and medial temporal lobe segmented into
CA3/DG (brown), CA1-2 transition (yellow), CA1
(blue), Subiculum (green), and entorhinal cortex
(red).
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tion compared to younger adults during the response phase
of a working memory task (Rypma and D’Esposito, 2000), with
faster response time in the older subjects associated with
greater activation. Studies of cognitive control have also been
productive in establishing unique age-related mechanisms of
impairment. Such studies have shown reductions in suppression
of task-irrelevant information by PFC in older, compared to
younger people (Gazzaley et al., 2005), as well as failure to shift
between functional brain networks after interruption (Clapp et al.,
2011). These functional alterations reflect predominant age-
related effects on PFC, which could reflect some of the synaptic
alterations seen in aging, although the actual mechanism of
these changes is unknown.
Summary and Conclusions
The behavioral and neural alterations associated with aging
affect the medial temporal and frontostriatal systems that
underlie episodic memory and executive function. In addition,
there is considerable evidence for age-related disruption of the
DMN and, within the medial temporal lobe, dysfunction in the
DG/perforant pathway system. Deposition of brain Ab has
substantial effects on both medial temporal and neocortical
systems that are involved in memory function. NFT pathology
affects the entorhinal cortex and perforant pathway. Loss of
dopamine has effects on the frontostriatal/executive system.
CVD affects both medial temporal and frontostriatal systems.
The DMN is affected by age, Ab, CVD, and dopamine deficiency.
Is cognitive aging just the aggregation of these disorders, or
something else?
We can draw important inferences from the small number of
studies that findmany of the AD-like age-related changes persist
in older people screened for fibrillar Ab. It remains possible that
such subjects have still not been adequately screened to rule out
early neurodegeneration like AD. This is an important concept
that reflects our current ignorance about what truly constitutes
AD. Is AD simply fibrillar Ab that can be detected with PET? Or
does it reflect soluble Ab, diffuse Ab plaques, NFTs (without
Ab), or even synaptic loss? It is impossible to completely differ-entiate age and AD until we know what AD is. Similar concerns
apply to the other age-related neurodegenerations.
However, the observation that the same neural systems can
be affected by more than one process also raises fundamental
questions about our understanding of aging itself. If the episodic
memory system is affected in individuals with and without Ab,
and the frontostriatal system is affected by conditions as varied
as CVD, dopamine deficiency, and age-related synaptic loss,
perhaps the question is not whether disease affects these
systems, but rather how such systems are vulnerable to so
many different processes. In other words, these neural systems
are highly susceptible to multiple factors, including those that
can be clearly ascribed to our current conceptualizations of
disease, and those that do not fit such neat categories. This
explanation highlights aging as a process that reflects systemic
vulnerabilities to a variety of deleterious factors that accumulate
with the passage of time. Some of these factors are disease
related and others are not.
The important question therefore is not whether a disease
accounts for the change we see with age, but whether we can
unravel the fundamental mechanisms that produce changes in
the neural systems under discussion. If we can indeed identify
fundamental mechanisms responsible for the degeneration of
these systems, we may be on the road to developing methods
that increase brain health in the face of many different diseases
and even age itself. Answering these questions will no doubt be
enhanced by the dramatic improvement in our ability to detect
biomarkers of disease in asymptomatic people so that we may
define how our current understanding of disease relates to our
current understanding of aging. While this may not provide an
ultimate accounting of mechanisms underlying age-related
change, it may speed therapeutic approaches not only to what
we now consider overt disease but to age-related decline that
is based in fundamental mechanisms of neural vulnerability.ACKNOWLEDGMENTS
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